Australian Pharmaceutical Industries SWOT Analysis, Competitors, Segmentation, Target Market, Positioning & USP

Australian Pharmaceutical Industries

Pharmaceuticals

Pharma and Healthcare

-

API is Australia's largest wholesale distributor of pharmaceutical and allied products.

People who looking for quality drugs for health and beauty purposes.

Healthcare professionals, wholesalers, generic distributors, and hospitals

API is involved in pharmaceutical distribution, retailing and manufacturing of health and beauty products.

Below are the Strengths in the SWOT Analysis of Australian Pharmaceutical Industries:

1. Offers a broad range of pharmacy services, including wholesale product delivery, retail services, marketing programs and business advisory services
2. A number of landmark products and banners.

3. The retail footprint allows for good growth.
4.Niche player in over-the-counter pharmaceuticals and toiletries

5. Its subsidiaries include Priceline, Priceline Pharmacy, Soul Pattinson, Pharmacists Advice

Here are the weaknesses in the Australian Pharmaceutical Industries SWOT Analysis:

1. Alleged accounting discrepancies & Sigma takeover controversies affected the brand

2. The company may lose focus if they enter into different segments (personal care, well-being products) all together

3. The market is dominated (90% of market) by 3 major players – API, Sigma, and Symbion Health; gaining more market share is a difficult task

Following are the Opportunities in Australian Pharmaceutical Industries SWOT Analysis:

1. Awareness about healthcare is rapidly increasing, API has a huge space to come up with healthcare and well-being products

2. It can divest pharmaceutical assets which could help the company in increasing its focus on core business

3.There is scope for development in areas of well-being and personal care.

The threats in the SWOT Analysis of Australian Pharmaceutical Industries are as mentioned:

1. Reforms in pharmaceutical pricing scheme namely PBS reforms can create trouble for the company

2. The margins of the company may be hurt because of PBS because it may create a trade barrier between Australian and U.S. drug companies

3. Stringent rules against clinical trials and quality of drugs will require more stringent measures from the company leading to increased costs

Below are the top 3 Australian Pharmaceutical Industries competitors:

1. Sigma Pharmaceuticals

2. Symbion Health

3. Alphapharm